Fractures in users of antidepressants and anxiolytics and sedatives: effects of age and dose
- 440 Downloads
Antidepressants have been associated with fractures. In a case–control study, increasing age was associated with more fractures in users of selective serotonin reuptake inhibitors and tricyclic antidepressants, whereas for anxiolytics and sedatives, more fractures were seen among the younger users. Depression per se did not seem associated with fractures.
This study aims to study the effects of age and dose of selective serotonin reuptake inhibitors (SSRI), tricyclic antidepressants (TCA) and anxiolytics/sedatives on fracture risk.
The study was designed as a case–control study. From the Danish National Health Service, we identified 124,655 fracture cases and 373,962 age- and gender-matched controls. Crude odds ratios were estimated, and propensity score adjustment was used to minimise confounding by indication.
A higher risk of fractures was associated with an increasing dose of anxiolytics and sedatives; the highest excess risk was present in the age stratum below 40 years of age (p < 0.01), and thereafter, the excess risk of fractures declined with age. For SSRI, a growing excess risk of fractures was seen with both increasing dose and age. Regarding TCA, no particular trend with age was present. However, an increasing risk of fractures was associated with increasing TCA dose in the age group above 60 years. Finally, for other antidepressants, no particular trend with age or dose was observed. In our data, a hospital diagnosis of depression or manic depression was associated with fewer fractures.
Caution should be shown upon prescription of SSRI to older subjects. A hospital diagnosis of depression or manic depression and thus potentially a more severe disease was not a risk factor for fractures.
KeywordsAntidepressant Fracture Selective serotonin reuptake inhibitors Tricyclic antidepressants
Danmarks Statistik (Statistics Denmark) is acknowledged for the help, without which this project would not have been possible. This study was made possible through a grant by the A.P. Møller Foundation (Fonden til Lægevidenskabens Fremme) and the Danish Medical Research Council (grant number 22-04-0495). The sponsors had no role in obtaining, analysing and interpreting the data.
Conflicts of interest
- 5.Atteritano M, Lasco A, Mazzaferro S, Macrì I, Catalano A, Santangelo A, Bagnato G, Bagnato G, Frisina N (2011) Bone mineral density, quantitative ultrasound parameters and bone metabolism in postmenopausal women with depression. Intern Emerg Med. doi: 10.1007/s11739-011-0628-1
- 11.Capella D (1993) Descriptive tools and analysis. In: Dukes MNG (ed) Drug utilization studies: methods and uses. World Health Organization, Copenhagen, pp 55–78Google Scholar
- 12.Nielsen G, Sørensen H, Zhou W, Steffensen F, Olsen J (1997) The pharmaco-epidemiologic prescription database of North Jutland. Int J Risk Saf Med 10:203–205Google Scholar
- 18.Prieto-Alhambra D, Javaid MK, Judge A, Maskell J, Kiran A, Cooper C, Arden NK (2011) Bisphosphonate use and risk of post-operative fracture among patients undergoing a total knee replacement for knee osteoarthritis: a propensity score analysis. Osteoporos Int 22:1555–1571PubMedCrossRefGoogle Scholar
- 26.Haney EM, Chan BK, Diem SJ, Ensrud KE, Cauley JA, Barrett-Connor E, Orwoll E, Bliziotes M, for the Osteoporotic Fractures in Men Study Group (2007) Association of low bone mineral density with selective serotonin reuptake inhibitor use by older men. Arch Intern Med 167:1246–1251CrossRefGoogle Scholar
- 27.Pollock B (1999) Adverse reactions of antidepressants in elderly patients. J Clin Psychiat 60(Suppl 20):4–8Google Scholar
- 32.World Health Organization (2003) Prevention and management of osteoporosis. WHO technical report series no 921. WHO, GenevaGoogle Scholar